50090-2867 : Dorzolamide Hcl and Timolol Maleate Ophthalmic Solution


NDC50090-2867
Labeler: A-s Medication Solutions
Product Type: Human Prescription Drug
Drug Name:  Dorzolamide Hcl and Timolol Maleate
Dosage Form: Ophthalmic Solution
Application #: ANDA202054
Rev. Date: 


NDC Package Codes:

  • 50090-2867-0: 1 BOTTLE, DISPENSING IN 1 CARTON (50090‑2867‑0) > 10 ML IN 1 BOTTLE, DISPENSING

Active Ingredients:

  • Dorzolamide Hydrochloride
  • Timolol Maleate

Dosage Strength:

  • 20 mg/mL
  • 5 mg/mL

Pharmaceutical Classes:

  • Carbonic Anhydrase Inhibitor [EPC]
  • Carbonic Anhydrase Inhibitors [MoA]
  • Adrenergic beta-Antagonists [MoA]
  • beta-Adrenergic Blocker [EPC]

Related Products:

Based on records with the same trade name.
  • 0591-2482 Dorzolamide Hcl and Timolol Maleate Ophthalmic Solution by Actavis Pharma, Inc.
  • 17478-514 Dorzolamide Hcl and Timolol Maleate Ophthalmic Solution/ Drops by Akorn, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 50090-2867 QR Code

< Prev: 50090-2866Next: 50090-2868 >

Related Discussions:

Dorzolamide-timolol opth
Has anyone taken the generic verision of Dorzolamide-Timolol and is it as good as the non-generic verision? Thanks. s. h... 1 reply
Dorzolamide - Timolol Opth Soln 10 ML
I have been on Dorzolamide - Timolol for the past eight months , for use in one eye . This drug has reduced my eye press... 1 reply
Is there any new eye drops for glaucoma iop control I am already using latanoprost xalatan and timolol maleate and Alphagan
I am using all the three drops but i feel my iop is still not under control. Would there be any new drug out in market ?...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.